Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta
Egbe, A, Reddy, Yogesh N.V. , Ali, Ahmed E. , Younis, Ahmed , Nishimura, Rick , Egbe, Alexander C. , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | July 17, 2024 | Volume: 26 | Issue: 12 | Pages: 2595-2603

10.1002/ejhf.3379 | PMID 39014871 Get It

Aims There are similarities in the pathogenesis of cardiac remodelling and dysfunction in heart failure with preserved ejection fraction (HFpEF) and coarctation of aorta (COA). We hypothesized that clinical HFpEF would be highly prevalent in adults with COA, and that the presence of HFpEF would increase the risk of mortality in this population. The aim of this study was to define the clinical features, haemodynamics, and prognostic implications of HFpEF in COA. Methods and results Consecutive adults with repaired COA that underwent right heart catheterization were identified retrospectively. HFpEF was defined as heart failure symptoms (exertional dyspnoea or fatigue), preserved left ventricular ejection fraction ≥50%, and pulmonary artery wedge pressure at rest >15 mmHg. Of 99 COA patients, 32 (32%) had HFpEF. The correlates of HFpEF were obesity (adjusted odds ratio [OR] 4.15, 95% confidence interval [CI] 1.31–13.2), atrial fibrillation (adjusted OR 3.13, 95% CI 1.00–10.7), total arterial compliance index (adjusted OR 0.12, 95% CI 0.06–0.41 per 1 ml/mmHg*m 2 ), and pulmonary artery compliance index (adjusted OR 0.36, 95% CI 0.15–0.56 per 1 ml/mmHg*m 2 ). Of 99 patients, 24 (24%) died and 5 (5%) underwent heart transplant. The 10‐year cumulative incidence of death/transplant was higher in COA patients with HFpEF compared with patients without HFpEF (39% vs. 12%, p = 0.001). The presence of HFpEF was associated with increased risk of death/transplant (adjusted hazard ratio 1.68, 95% CI 1.16–3.11). Conclusions Heart failure with preserved ejection fraction is common in adults with COA and is associated with greater risk of death/transplant, emphasizing a pressing need for interventions to prevent and treat HFpEF in COA.
Transforming Hypertension Diagnosis and Management in The Era of Artificial Intelligence: A 2023 National Heart, Lung, and Blood Institute (NHLBI) Workshop Report
Shimbo, Daichi , Abdalla, Marwah , Agarwal, Ritu , Ahmad, Faraz S. , Anaya, Gabriel , Attia, Zachi I. , Bull, Sheana , Chang, Alex R. , Commodore‐Mensah, Yvonne , Ferdinand, Keith C. , Oh, Young S. , Savage, Lucia , Turakhia, Mintu P. , Whelton, Paul K. , Iturriaga, Erin , Shah, Rashmee U , Abdalla, Marwah , Ahmad, Faraz , Anaya, Gabriel , Attia, Zachi I , Chang, Alexander R , Commodore-Mensah, Yvonne , Ferdinand, Keith , Kawamoto, Kensaku , Khera, Rohan , Leopold, Jane A , Makhni, Sonya , Mortazavi, Bobak J , Savage, Lucia C , Spatz, Erica S , Stergiou, George , Turakhia, Mintu P , Whelton, Paul K , Yancy, Clyde W. , Iturriaga, Erin , Shah, Rashmee U. , Khera, Rohan , Leopold, Jane A. , Luo, James N. , Mortazavi, Bobak J. , Spatz, Erica S. , Stergiou, George S.

Mayo Clinic

Hypertension | July 16, 2024 | Volume: 82 | Issue: 1 | Pages: 36-45

10.1161/hypertensionaha.124.22095 | PMID 39011653 Get It

Hypertension is among the most important risk factors for cardiovascular disease, chronic kidney disease, and dementia. The artificial intelligence (AI) field is advancing quickly, and there has been little discussion on how AI could be leveraged for improving the diagnosis and management of hypertension. AI technologies, including machine learning tools, could alter the way we diagnose and manage hypertension, with potential impacts for improving individual and population health. The development of successful AI tools in public health and health care systems requires diverse types of expertise with collaborative relationships between clinicians, engineers, and data scientists. Unbiased data sources, management, and analyses remain a foundational challenge. From a diagnostic standpoint, machine learning tools may improve the measurement of blood pressure and be useful in the prediction of incident hypertension. To advance the management of hypertension, machine learning tools may be useful to find personalized treatments for patients using analytics to predict response to antihypertension medications and the risk for hypertension-related complications. However, there are real-world implementation challenges to using AI tools in hypertension. Herein, we summarize key findings from a diverse group of stakeholders who participated in a workshop held by the National Heart, Lung, and Blood Institute in March 2023. Workshop participants presented information on communication gaps between clinical medicine, data science, and engineering in health care; novel approaches to estimating BP, hypertension risk, and BP control; and real-world implementation challenges and issues.
In vitro evaluation of flow diverter performance using a human fibrinogen–based flow model
Bilgin, Cem , Kallmes, David F. , Kadirvel, Ramanathan , Bayraktar, Esref Alperen , Oliver, Alexander A , Li, Jiahui , Cebral, Juan R.

Mayo Clinic

Journal of Neurosurgery | July 12, 2024 | Volume: 142 | Issue: 1 | Pages: 154-161

10.3171/2024.4.jns232567 | PMID 38996402 Get It

OBJECTIVE Fibrin deposition represents a key step in aneurysm occlusion, promoting endothelization of implants and connective tissue organization as part of the aneurysm-healing mechanism. In this study, the authors introduce a novel in vitro testing platform for flow diverters based on human fibrinogen. METHODS A flow diverter was deployed in 4 different glass models. The glass models had the same internal parent artery (4 mm) and aneurysm (8 mm) diameters with varying parent artery angulations (paraophthalmic, sidewall, bifurcation, and slightly curved models). The neck size and area were 4 mm and 25 mm 2 , respectively. Human fibrinogen (330 mg/dl) was circulated within the glass models at varying flow rates (0, 3, 4, and 5 ml/sec) with or without heparin, calcium chloride, and thrombin for as long as 6 hours or until complete fibrin coverage of the flow diverter’s neck was achieved. Aneurysm neck coverage was defined as macroscopic fibrin deposition occluding the flow diverters’ pores. Flow characteristics after flow diverter deployment were assessed with computational fluid dynamics analysis. The effects of flow rates, heparin, calcium chloride, and thrombin on fibrin deposition rates were tested using 1-way ANOVA and the Tukey test. RESULTS A total of 84 replicates were performed. Human fibrin did not accumulate on the flow diverter stents under static conditions. The fibrin deposition rate on the aneurysm neck was significantly greater with the 5 ml/sec flow rate as compared to 3 ml/sec for all models. The paraophthalmic model had the highest inflow velocity of 48.7 cm/sec. The bifurcation model had the highest maximum shear stress (SS) and maximum normalized shear stress values at the device cells at 843.3 dyne/cm 2 and 35.1 SS/SS inflow , respectively. The fibrin deposition rates of the paraophthalmic and bifurcation models were significantly higher than those of sidewall and slightly curved models for all additive or flow rate comparisons (p = 0.001 for all comparisons). The incorporation of thrombin significantly increased the fibrin deposition rates across all models (p = 0.001 for all models). CONCLUSIONS Rates of fibrin deposition varied widely across different configurations and additive conditions in this novel in vitro model system. Fibrin accumulation started at the aneurysm inflow zone where flow velocity and shear stress were the highest. The primary factors influencing fibrin deposition included flow velocities, shear stress, and the addition of thrombin at a physiological concentration. Further research is needed to test the clinical utility of fibrinogen-based models for patient-specific aneurysms.
Triceps-to-Biceps Tendon Transfer Technique for Restoration of Elbow Flexion in Adult Brachial Plexus Injury
Weber, Morgan B. , Townsley, Sarah, Spinner, Robert J. , Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Techniques in Hand & Upper Extremity Surgery | July 12, 2024 | Volume: 28 | Issue: 4 | Pages: 214-223

10.1097/bth.0000000000000491 | PMID 38995200 Get It

Restoration of elbow flexion is a priority in treating adult traumatic brachial plexus injuries. A tendon transfer is an ideal option for patients not candidates for reconstructive nerve surgery or free-functioning muscle transfer. For patients with a partial brachial plexus injury or a pan plexus injury with adequate recovered triceps function and loss of elbow flexion, a triceps-to-biceps tendon transfer is a nonmicrosurgical option to restore elbow flexion. The technique of triceps-to-biceps transfer in which the complete triceps tendon is transferred laterally, secured lateral to the radial tuberosity, and reinforced with suture to the biceps tendon is described.
A scoping review of geriatric emergency medicine research transparency in diversity, equity, and inclusion reporting
Suh, Michelle , Ordoñez, Edgardo , Cameron, Lauren , Ahmad, Surriya, Zirulnik, Alexander , Landry, Alden , Spencer, Vivian , Obi, Tracey, Weaver, Emily H., Carpenter, Christopher R , Chary, Anita Nandkumar , Hardi, Angela , Weaver, Emily H., Carpenter, Christopher R.

Mayo Clinic

Journal of the American Geriatrics Society | July 12, 2024 | Volume: 72 | Issue: 11 | Pages: 3551-3566

10.1111/jgs.19052 | PMID 38994587 Get It

Abstract Introduction The intersection of ageism and racism is underexplored in geriatric emergency medicine (GEM) research. Methods We performed a scoping review of research published between January 2016 and December 2021. We included original emergency department‐based research focused on falls, delirium/dementia, medication safety, and elder abuse. We excluded manuscripts that did not include (1) original research data pertaining to the four core topics, (2) older adults, (3) subjects from the United States, and (4) for which full text publication could not be obtained. The primary objective was to qualitatively describe reporting about older adults' social identities in GEM research. Secondary objectives were to describe (1) the extent of inclusion of minoritized older adults in GEM research, (2) GEM research about health equity, and (3) feasible approaches to improve the status quo of GEM research reporting. Results After duplicates were removed, 3277 citations remained and 883 full‐text articles were reviewed, of which 222 met inclusion criteria. Four findings emerged. First, race and ethnicity reporting was inconsistent. Second, research rarely provided a rationale for an age threshold used to define geriatric patients. Third, GEM research more commonly reported sex than gender. Fourth, research commonly excluded older adults with cognitive impairment and speakers of non‐English primary languages. Conclusion Meaningful assessment of GEM research inclusivity is limited by inconsistent reporting of sociodemographic characteristics, specifically race and ethnicity. Reporting of sociodemographic characteristics should be standardized across different study designs. Strategies are needed to include in GEM research older adults with cognitive impairment and non‐English primary languages.
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
Chien, A. Jo , Wei, Mei , Veer, Laura van 't, Alkhafaji, Silver , Chen, Nan , Borowsky, Alexander D. , Hylton, Nola, Mukhtar, Rita A. , Giridhar, Karthik V. , Olopade, Olufunmilayo I. , Kalinsky, Kevin M. , Vaklavas, Christos , Elias, Anthony , Goetz, Matthew P. , Rugo, Hope S. , Symmans, W. Fraser , Swigart, Lamorna Brown , Onishi, Natsuko , Yee, Douglas , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | July 11, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 601-601

10.1200/jco.2024.42.16_suppl.601 Get It

601 Background: EOP is an I-SPY2 neoadjuvant sub-study designed to test the tolerability and impact of novel endocrine-based strategies in stage 2/3 BC pts predicted to have lower benefit from chemotherapy. Amcenestrant (A) is an oral selective estrogen receptor degrader (SERD) with activity in hormone receptor positive (HR+) HER2- metastatic BC. Methods: EOP eligibility included pts screened for the main I-SPY2 trial with HR+ HER2-, MammaPrint (MP) low risk Stage 2/3 BC. Pts with MP High risk tumor signatures were eligible if clinically node-negative (cN-). Pts were stratified by SET index and menopausal status. Pts were randomized to 3 arms: A 200 mg qd (A), A + abemaciclib 150 mg bid (AA), A + letrozole 2.5 mg qd (AL). Premenopausal pts received concurrent ovarian function suppression. Treatment was for 6 mos followed by surgery. Baseline (BL) and 3-wk biopsies were performed. Breast MRIs were conducted at BL (T0), 3 wks (T1), 12 wks (T2), 6 mos (T3). The primary endpoint was feasibility, defined as >75% of pts completing >75% study therapy. Results: Between May 2021 and Aug 2022, 74 pts were randomized: 31 A, 21 AA, 22 AL. Median age 50 years, 54% premenopausal, 38% clinically node-positive (cN+). 41% pts had ductal, 38% lobular, 11% mixed ductal/lobular histology. Mean BL tumor Ki67 (central testing) was 16.9%, 88% MP low, 76% SET index Hi. Pt and tumor characteristics were balanced across the 3 arms. Treatment in all 3 arms was feasible with 95% of pts completing >75% study therapy. Most common AEs include grade 1-2 hot flashes (69%) and fatigue (66%). Grade 3 AEs include neutropenia (2 pts) and diarrhea (1 pt) in AA. Table summarizes key response endpoints, which were similar between pre- and postmenopausal pts. Of 28 cN+ pts, 2 (7%) were pathologically node-negative (pN-). Mean MRI Functional Tumor Volume (cc) change between T0->T1, T1->T2, T2->T3, T0->T3 was -6.06 (-34.2%), -3.55 (-29.2%), -0.829 (-20.1%), -11.3 (-68.4%), respectively, similar across arms (p=0.396).ctDNA was detected in 10/59 (17%) pts at T0. ctDNA became undetectable in 6 pts, decreased in 4 pts, and went from ctDNA undetectable at baseline to detectable at T3 in 2 pts. Conclusions: Six months of neoadjuvant endocrine therapy (NET) with the oral SERD amcenestrant is feasible, well-tolerated, and demonstrates anti-proliferative and anti-tumor activity in pre- and postmenopausal pts. NET provides a rich platform for biomarker discovery and investigating response to endocrine therapy. Clinical trial information: NCT01042379 . [Table: see text]
CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
Pophali, Priyanka A. , Ahn, Kwang Woo , Allbee-Johnson, Molly, Ahmed, Nausheen , Awan, Farrukh T. , Farhan, Shatha , Grover, Natalie S. , Hilal, Talal , Modi, Dipenkumar , Nasrollahi, Elham , Schachter, Levanto , Sauter, Craig S. , Herrera, Alex F. , Ahn, Kwang W , Ahmed, Nausheen , Awan, Farrukh T , Farhan, Shatha , Grover, Natalie S , Hilal, Talal , Modi, Dipenkumar , Hamadani, Mehdi , Herrera, Alex F , Shadman, Mazyar , Pophali, Priyanka , Fein, Joshua Alexander , Iqbal, Madiha , Maakaron, Joseph E. , Hamadani, Mehdi , Shouval, Roni , Shadman, Mazyar

Mayo Clinic

Blood Advances | July 10, 2024 | Volume: 8 | Issue: 20 | Pages: 5290-5296

10.1182/bloodadvances.2024013863 | PMID 38985302 Get It

Abstract T-cell/histiocyte–rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19–directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We investigated CART outcomes for R/R THRLBCL through the Center for International Blood and Marrow Transplant Research registry. A total of 58 adult patients with R/R THRLBCL who received commercial CD19-CART therapy between 2018 and 2022 were identified. Most patients (67%) had early relapse of disease (45% primary refractory) with a median of 3 (range, 1-7) prior therapies and were treated with axicabtagene ciloleucel (69%). At median follow-up of 23 months after CART therapy, 2-year overall and progression-free survival were 42% (95% confidence interval [CI], 27-57) and 29% (95% CI, 17-43), respectively. In univariable analysis, poor performance status before CART therapy was associated with higher mortality (hazard ratio, 2.35; 95%CI, 1.02-5.5). The 2-year cumulative incidences of relapse/progression and nonrelapse mortality were 69% and 2%, respectively. Grade ≥3 cytokine release syndrome and immune effector cell–associated neurologic syndrome occurred in 7% and 15% of patients, respectively. In this largest analysis of CD19-CART therapy for R/R THRLBCL, ∼30% of patients were alive and progression free 2 years after CART therapy. Despite a high incidence of progression (69% at 2 years), these results suggest a subset of patients with R/R THRLBCL may have durable responses with CARTs.
Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
Ulugut, Hülya , Samancı, Bedia , Illán‐Gala, Ignacio , Kuchcinski, Grégory , Leroy, Mélanie , Santillo, Alexander , Waldö, Maria Landqvist , Riedl, Lina , Stock, Jan Van den , Vandenbulcke, Mathieu , Ducharme, Simon , Pressman, Peter , Takada, Leonel Tadao , Diehl‐Schmid, Janine , Galimberti, Daniela , Barkhof, Frederik , Sturm, Virginia E. , Miyagawa, Toji , Whitwell, Jennifer L. , Rohrer, Jonathan D. , Gorno‐Tempini, Maria Luisa, Josephs, Keith A. , Warren, Jason D. , Rankin, Katherine P. , Group, International rtvFTD Working, Barkhof, Frederik , Rohrer, Jonathan D , Illán-Gala, Ignacio , Galimberti, Daniela , Bertoux, Maxime , Younes, Kyan , Montembeault, Maxime , Fumagalli, Giorgio , Thompson, J. C. , Kobylecki, Christopher , Englund, Elisabet , Vandenberghe, Rik , Laforce, Robert , Caramelli, Paulo , Souza, Leonardo Cruz de , Gurvit, Hakan I. , Hansson, Oskar , Pasquier, Florence , Miller, Bruce L. , Scheltens, Philip , Ossenkoppele, Rik , Flier, Wiesje M. van der , Fox, Nick C. , Boeve, Bradley F. , Gorno‐Tempini, Maria‐Luisa, Snowden, Julie S. , Pijnenburg, Yolande A.L. , Group, International rtvFTD Working

Mayo Clinic

Alzheimer's & Dementia | July 10, 2024 | Volume: 20 | Issue: 8 | Pages: 5647-5661

10.1002/alz.14076 | PMID 38982845 Get It

Abstract INTRODUCTION Although frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance has been recognized, a uniform description of the syndrome is still missing. This multicenter study aims to establish a cohesive clinical phenotype. METHODS Retrospective clinical data from 18 centers across 12 countries yielded 360 FTD patients with predominant RATL atrophy through initial neuroimaging assessments. RESULTS Common symptoms included mental rigidity/preoccupations (78%), disinhibition/socially inappropriate behavior (74%), naming/word‐finding difficulties (70%), memory deficits (67%), apathy (65%), loss of empathy (65%), and face‐recognition deficits (60%). Real‐life examples unveiled impairments regarding landmarks, smells, sounds, tastes, and bodily sensations (74%). Cognitive test scores indicated deficits in emotion, people, social interactions, and visual semantics however, lacked objective assessments for mental rigidity and preoccupations. DISCUSSION This study cumulates the largest RATL cohort unveiling unique RATL symptoms subdued in prior diagnostic guidelines. Our novel approach, combining real‐life examples with cognitive tests, offers clinicians a comprehensive toolkit for managing these patients. Highlights This project is the first international collaboration and largest reported cohort. Further efforts are warranted for precise nomenclature reflecting neural mechanisms. Our results will serve as a clinical guideline for early and accurate diagnoses.
Body Checking Injuries in National Collegiate Athletic Association Men's Ice Hockey: Findings From the NCAA Injury Surveillance Program 2009/10 to 2019/20
Boltz, Adrian J. , Garcia, Reagan E., Collins, Christy L. , Alexander, Andrew , Alexander, Andrew S , Alexander, Andrew S., Mihalik, Jason P. , Chandran, Avinash S.

Mayo Clinic

Clinical Journal of Sport Medicine | July 9, 2024 | Volume: 34 | Issue: 6 | Pages: 583-590

10.1097/jsm.0000000000001255 | PMID 38980686 Get It

Objective: To describe the epidemiology of body checking injuries in the National Collegiate Athletic Association (NCAA) Men's Ice Hockey. Design: Secondary data analysis of historical cohort data. Setting: A convenience sample of injuries in NCAA Men's Ice Hockey during the 2009/10 to 2019/20 academic years. Patients (or Participants) NCAA student-athletes. Independent Variables: Event type, season, time loss, body part, diagnosis, player position, and mechanism. Main Outcome Measures: This study examined injuries that occurred during practice or competition, regardless of time loss, reported to the NCAA Injury Surveillance Program. Injury counts, rates, and proportions were used. The injury rate and proportion ratios with 95% confidence intervals were also constructed. Three independent logistic regression models were constructed to examine differential odds of time loss (≥1 day; TL) injury and the 2 most common injuries, between body checking injuries and all other injuries. Results: Overall, 1290 body checking injuries (rate = 1.59/1000 athlete-exposures) were reported during the study period. Most were attributed to the upper extremity (42%) or head/neck (27%). The competition injury rate generally decreased after 2012/13. After adjusting for covariates, odds of (1) a TL injury was lower and (2) an acromioclavicular sprain was higher among body checking injuries as compared with injuries attributed to all other activities. Odds of concussion was not associated with body checking injuries. Conclusions: Body checking injuries were frequently attributed to the head/neck and upper extremities, and the rate of these injuries during competition appeared to be decreasing. Still, improvements in helmet and shoulder pad technology may further improve health and safety.
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Akahoshi, Yu , Spyrou, Nikolaos , Weber, Daniela , Aguayo‐Hiraldo, Paibel , Ayuk, Francis , Chanswangphuwana, Chantiya , Choe, Hannah , Etra, Aaron , Grupp, Stephan A. , Schechter, Tal , Vášová, Ingrid, Wölfl, Matthias , Baez, Janna , Beheshti, Rahnuma, Eng, Gilbert, Gleich, Sigrun, Katsivelos, Nikolaos , Kowalyk, Steven, Morales, George , Young, Rachel , Chen, Yi‐Bin , Nakamura, Ryotaro , Ferrara, James L.M. , Grupp, Stephan A , Hexner, Elizabeth , Hogan, William J , Al Malki, Monzr M , Merli, Pietro , Qayed, Muna , Reshef, Ran , Ullrich, Evelyn , Katsivelos, Nikolaos , Chen, Yi-Bin , Nakamura, Ryotaro , Levine, John E , Ferrara, James L M , Aguayo-Hiraldo, Paibel , Akahoshi, Yu , Eder, Matthias , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Zeiser, Robert , Levine, John E.

Mayo Clinic

Blood | July 5, 2024 | Volume: 144 | Issue: 9 | Pages: 1010-1021

10.1182/blood.2024025106 | PMID 38968143 Get It

Abstract Acute graft-versus-host disease (GVHD) grading systems that use only clinical symptoms at treatment initiation such as the Minnesota risk identify standard and high-risk categories but lack a low-risk category suitable to minimize immunosuppressive strategies. We developed a new grading system that includes a low-risk stratum based on clinical symptoms alone and determined whether the incorporation of biomarkers would improve the model’s prognostic accuracy. We randomly divided 1863 patients in the Mount Sinai Acute GVHD International Consortium (MAGIC) who were treated for GVHD into training and validation cohorts. Patients in the training cohort were divided into 14 groups based on similarity of clinical symptoms and similar nonrelapse mortality (NRM); we used a classification and regression tree (CART) algorithm to create three Manhattan risk groups that produced a significantly higher area under the receiver operating characteristic curve (AUC) for 6-month NRM than the Minnesota risk classification (0.69 vs 0.64, P = .009) in the validation cohort. We integrated serum GVHD biomarker scores with Manhattan risk using patients with available serum samples and again used a CART algorithm to establish 3 MAGIC composite scores that significantly improved prediction of NRM compared to Manhattan risk (AUC, 0.76 vs 0.70, P = .010). Each increase in MAGIC composite score also corresponded to a significant decrease in day 28 treatment response (80% vs 63% vs 30%, P < .001). We conclude that the MAGIC composite score more accurately predicts response to therapy and long-term outcomes than systems based on clinical symptoms alone and may help guide clinical decisions and trial design.